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Background: According to the 2008 World Health Organization classiﬁcation, mature B-cell
neoplasms are a heterogeneous group of diseases that include B-cell lymphomas and plasma
cell  disorders. These neoplasms can have very different clinical behaviors, from highly
aggressive to indolent, and therefore require diverse treatment strategies.
Objective: The aim of this study was to assess the proﬁle of 93 patients diagnosed with
mature B-cell neoplasms monitored between 2011 and 2014.
Methods: A review of patients’ charts was performed and laboratory results were obtained
using the online system of the Universidade Federal de Santa Catarina.
Results: The study included 93 adult patients with mature B-cell neoplasms. The most fre-
quent subtypes were multiple myeloma, chronic lymphocytic leukemia, diffuse large B-cell
lymphoma, follicular lymphoma, and Burkitt’s lymphoma. The median age at diagnosis was
58  years with a male-to-female ratio of 1.3:1. There were statistical differences in terms of
age at diagnosis, lactate dehydrogenase activity and Ki-67 expression among the subtypes
of  B-cell lymphoma. According to the prognostic indexes, the majority of multiple myeloma
patients were categorized as high risk, while the majority of chronic lymphocytic leukemia
patients were classiﬁed as low risk.
Conclusions: This study demonstrates the proﬁle of patients diagnosed with mature B-cell
neoplasms in a south Brazilian university hospital. Of the B-cell lymphoma, Burkitt’s lym-
phoma presented particular features regarding lactate dehydrogenase activity levels, Ki-67
expression, age at diagnosis, and human immunodeﬁciency virus infection.©  2016 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published∗ Corresponding author at: Divisão de Análises Clínicas, Hospital Un
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Introduction
Mature B-cell neoplasms (MBCN) are a heterogeneous group of
diseases that comprises B-cell lymphomas (BCL) and plasma
cell neoplasms (PCN).1 About ﬁfteen subtypes of BCL and ﬁve
subtypes of PCN are categorized in the 2008 World Health
Organization (WHO) Tumors of Hematopoietic and Lymphoid
Tissues.1 MBCN present variable clinical presentations from
highly aggressive to indolent, and therefore require different
treatment strategies.2
Epidemiological data place MBCN as a substantial global
health problem. In the Western world with about 20 new cases
of lymphoma being diagnosed per 100,000 people annually,2
which accounts for 3–4% of all malignancies.3 Moreover, mul-
tiple myeloma (MM)  accounts for 1% of all malignancies, with
a global incidence of nearly 120,000 cases per year.4
Similar to other types of cancer, MBCN arise by multistep
accumulation of genetic aberrations that induce a selective
growth advantage of the malignant clone. Commonly, the ini-
tial steps in the malignant transformation are chromosomal
translocations, which might occur during different stages of
B-cell differentiation.5
In addition to the recent advances in the understanding
of genetic and genomic characteristics of B-cell malignan-
cies, remarkable effort has been made to understand potential
risk factors that account for the increase in the incidence
of MBCN, particularly in relation to the environment and
lifestyle. Severe immunosuppression resulting from immu-
nodeﬁciency syndromes and after organ transplantation, and
some infectious agents are known risk factors for the devel-
opment of some lymphoma subtypes.6 Much attention is
being paid to the high risk of lymphoma in human immu-
nodeﬁciency virus (HIV)-positive patients (60 to 200-fold).7
In addition, studies have suggested there is an increased
risk of lymphomas and MM in relation to the use of some
pesticides.8 Additionally, the contribution of environmental
factors, such as smoking, and lifestyle including diet remain
unclear.6
Considering the lack of Brazilian studies on this issue and
the lack of epidemiological data, the present study was con-
ducted to provide information about the proﬁle of patients
who have developed this type of neoplasm. Thus, the aim of
this study was to assess the proﬁle of 93 patients diagnosed
with MBCN monitored between 2011 and 2014 in a university
hospital in southern Brazil.
Methods
Study  participants
The subjects comprised adult patients diagnosed with MBCN
during the period covered by the study (June 2011–October
2014) and monitored at the university hospital of the Uni-
versidade Federal de Santa Catarina (UFSC), Florianópolis, SC,
Brazil. Patients were excluded if their records were unavail-
able or if they did not sign the consent form. This study was
approved by the Ethics Committee of the institution. The uni-
versity hospital of UFSC treats an average of 250,000 patients 2 0 1 6;3  8(2):121–127
per year. From this total, an average of 2400 patients per year
are attended at the Hematology Clinic and around 240 patients
per year are hospitalized by the Hematology Service.
Design
Clinical and personal data were obtained through a review
of patient charts from the hospital with the conﬁdentiality
of information being preserved. Laboratory test results were
obtained through the online hospital system. Clinical and lab-
oratory data were recorded on a data collection form and later
compiled for statistical analysis.
Collected data included variables such as age at diagno-
sis, year of diagnosis, gender, race/ethnicity, literacy, serology,
clinical manifestations at diagnosis, co-morbidities, labora-
tory exams at diagnosis, neoplasm stage or stratiﬁcation, and
outcome. Outcome was classiﬁed as one of two  categories:
complete/partial remission (CR/PR) and relapsed/progressive
disease (PD) based on previous established criteria.9,10 The
end of the data collection period was established as February
2015.
Statistical  analysis
Database preparation and statistical analysis were performed
using the Statistical Package for Social Sciences (SPSS® version
17.0) and MedCalc® (version 12.3.0.0). Data are presented as
descriptive statistics including absolute and relative frequen-
cies for categorical variables and measures of central tendency
and dispersion of continuous variables. Continuous variables
were tested for normality using the Kolmogorov–Smirnov
and Shapiro–Wilk tests. Numerical variables were compared
between groups using the Mann–Whitney U test or Student’s
t-test. A comparison of three or more  variables was performed
employing the Kruskal–Wallis test or one-way analysis of
variance (ANOVA). The frequencies obtained in categorical
variables were compared between patients by the chi-square
or Fisher’s exact test. A signiﬁcance level of 5% (p-value <0.05)
was considered signiﬁcant.
Results
Mature  B  cell  neoplasms
A total of 93 patients were diagnosed with a subtype of MBCN,
including BCL and PCN, from 2011 to 2014. The median age
at diagnosis was 58 years (range: 20–93 years) with a male-to-
female ratio of 1.3:1. Patient general characteristics are listed
in Table 1 and prevalence of the different subtypes of MBCN
cases are shown in Figure 1. The corresponding age distribu-
tions are shown in Figure 2.
Table 1 also shows the subtypes of MBCN that were diag-
nosed in patients with human immunodeﬁciency virus (HIV),cantly, one case of DLBCL was co-infected by HBV and HCV,
and one case each of BL and BCL unclassiﬁable (BCL-U) with
features intermediate between DLBCL and BL were co-infected
by HIV and HBV.
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Figure 1 – Prevalence of the mature B-cell neoplasms subgroups.
CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL: diffuse large B-cell lymphoma; BCL-U: B-cell
lymphoma, unclassiﬁable, with features intermediate between DLBCL and Burkitt’s lymphoma; MGUS: monoclonal
gammopathy of undetermined signiﬁcance; BCL-NOS: B-cell lymphoma, not otherwise speciﬁed; LPL/WM:
lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.
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Figure 2 – Age at diagnosis of mature B-cell neoplasms.
CLL/SLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL: diffuse large B-cell lymphoma; BCL-U: B-cell
lymphoma, unclassiﬁable, with features intermediate between DLBCL and Burkitt’s lymphoma; MGUS: monoclonal
gammopathy of undetermined signiﬁcance; BCL-NOS: B-cell lymphoma, not otherwise speciﬁed; LPL/WM:
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verall, 66 patients were diagnosed with a subtype of BCL.
here were statistical differences in terms of age at diagnosis
etween BL and chronic lymphocytic leukemia/small lympho-
ytic lymphoma (CLL/SLL – p-value = 0.001), BL and BCL not
therwise speciﬁed (BCL-NOS – p-value = 0.041), and BL and
antle cell lymphoma (MCL – p-value = 0.016). In addition,a.
in terms of serum lactate dehydrogenase (LDH) a statistical
difference (p-value = 0.003) was found between the different
groups (Table 2).
Regarding clinical parameters at the time of diagnosis, 17
patients (25.8%) presented B symptoms, 27 patients (40.9%)
lymphadenopathy, eight patients (12.1%) splenomegaly and
seven (10.6%) bulky disease. Of the 53 patients who  under-
went bone marrow examination, 35 (66.0%) had bone marrow
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Table 1 – Patient general characteristics (n = 93).
Characteristic n %
Gender
Male 53 57.0
Female 40 43.0
Race
White 85 91.4
Other unspeciﬁed 4 4.3
Unknown 4 4.3
Literacy
Incomplete elementary school 40 43.0
Complete elementary school 13 14.0
Complete high school 30 32.3
Complete higher education 9 9.7
Unknown 1 1.1
HIV
Positive 9 9.7
Negative 65 69.9
Unknown 19 20.4
HBV
Positive 5 5.4
Negative 66 71.0
Unknown 22 23.7
HCV
Positive 2 2.2
Negative 69 74.2
Unknown 22 23.7
Smoker
Non-smoker 3 3.2
Ex-smoker 11 11.8
Smoker 12 12.9
Passive smoker 1 1.1
Unknown 66 71.0
Exposure to pesticides
Absent 86 82.5
Present 7 7.5
Previous neoplasia
Absent 87 93.5
Present 6 6.5
Diabetes
Absent 77 82.8
Present 16 17.2
Hypertension
Absent 49 52.7
Present 44 47.3
HIV positive
(n = 9)
Burkitt’s lymphoma (n = 4)
Multiple myeloma (n = 1)
BCL-U (n = 2)
Plasmablastic lymphoma (n = 2)
HBV positive
(n = 5)
Follicular lymphoma (n = 1)
DLBCL (n = 1)
Burkitt’s lymphoma (n = 1)
Hairy cell leukemia (n = 1)
BCL-U (n = 1)
HCV positive
(n = 2)
DLBCL (n = 1)
BCL-U (n = 1)
MBCN: mature B-cell neoplasm; HIV: human immunodeﬁciency
virus; HBV: hepatitis B virus; HCV: hepatitis C virus; DLBCL: diffuse
large B-cell lymphoma; BCL-U: B-cell lymphoma, unclassiﬁable with
features intermediate between DLBCL and Burkitt’s lymphoma.
Table 2 – Serum lactate dehydrogenase activity in
patients diagnosed with B-cell lymphoma (n = 66).
BCL subtype LDH (IU/L)
Median (range)
CLL/SLL 188 (116–332)a
Diffuse large B-cell lymphoma 406 (184–2739)b
Follicular lymphoma 229 (150–315)a
Burkitt’s lymphoma 1534 (243–7239)b
BCL-U 464 (170–6121)b
Hairy cell leukemia 152 (141–402)a
Marginal zone lymphoma 137 (113–397)a
BCL-NOS 215 (182–232)a
Mantle cell lymphoma 222
LPL/WM 214 (128–300)a
Plasmablastic lymphoma 174 (148–199)a
LDH: lactate dehydrogenase; CLL/SLL: chronic lymphocytic
leukemia/small lymphocytic lymphoma; BCL-U: BCL, unclassiﬁ-
able, with features intermediate between DLBCL and BL; BCL-NOS:
BCL not otherwise speciﬁed; LPL/WM: lymphoplasmacytic lym-
phoma/Waldenström macroglobulinemia.
There was a signiﬁcant difference between ‘a’ and ‘b’ by the
Kruskal–Wallis and Mann–Whitney U tests.
inﬁltration. In addition, 12 patients were evaluated regarding
central nervous system (CNS) involvement. Three patients
with BL and two with BCL-U had CNS inﬁltration.
Ki-67 expression was evaluated by immunohistochem-
istry (IHC) in 30 patients. Similar to LDH levels, a statistical
difference was found between groups (p-value = 0.013). The
subtypes with the highest Ki-67 expressions were DLBCL,
BL, and BCL-U with median Ki-67 expression of 80% (range:
50–95%), 92.5% (range: 50–95%), and 80% (range: 30–95%),
respectively. The median expression of Ki-67 for the CLL/SLL
group was 30% (range: 10–50%) and for the follicular lym-
phoma group it was 35% (range: 10–50%).
Most  common  mature  B  cell  neoplasms
The most common subtypes of MBCN found in the present
study involved 66 patients: MM (n = 22), CLL/SLL (n = 14), DLBCL
(n = 12), FL (n = 11) and BL (n = 7). Figure 3 shows stratiﬁcation of
patients by MBCN subtype. Response to treatment was evalu-
ated as CR/PR and PD (Figure 4). CLL/SLL presented the highest
frequency of CR/PR (87.5%), while BL presented the highest
frequency of PD (83.3%).
Discussion
The present study retrospectively analyzed the clinical and
laboratorial data of 93 MBCN patients in a Brazilian univer-
sity hospital. The frequencies of the MBCN subtypes found in
this study are similar to those described in international and
Brazilian studies.11,12
A study published in 2010 by the Hematological Malignancy
Research Network Group (HMRN), examined 8131 patients
diagnosed with hematological malignancies in the UK. Cases
were classiﬁed according to the ﬁrst edition of the WHO  clas-
siﬁcation published in 2001. The following were the most
common subtypes of MBCN: DLBCL (1098 cases), MM (876
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Figure 3 – Stratiﬁcation of patients with (A) multiple myeloma, (B) chronic lymphocytic leukemia/small lymphocytic
lymphoma, and (C) diffuse large B-cell lymphoma, follicular lymphoma and Burkitt’s lymphoma.
DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; BL: Burkitt’s lymphoma; ND: not deﬁned because of the
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ases), CLL/SLL (835 cases), FL (446 cases), marginal zone lym-
homa (390 cases), MCL  (100 cases), BL (54 cases), and hairy
ell leukemia (48 cases).11 The data that differs compared to
he present study is the frequency of BL, which in this report
as the ﬁfth most common MBCN subtype.
In Brazil, a study published in 2011 in the State of São
aulo on the prevalence of non-Hodgkin lymphoma (NHL) sub-
ypes in 546 cases reported the following frequencies: DLBCL
n 49.45% of the cases, FL in 7.69%, BL in 6.41%, diffuse and
mall cell lymphoma (unclassiﬁable) in 6.41%, and CLL/SLL in
.23%.12 Thus, the prevalence of BL in the State of São Paulo
Southeastern region of Brazil) is similar to that found in the
resent study; however, the prevalence of CLL/SLL is discord-
nt.
Moreover, Queiroga et al. demonstrated the distribution of
L in the ﬁve Brazilian regions and analyzed the cases in terms
f age (pediatric or adult), among other parameters. Interest-
ngly, BL in the southern region mainly affects adult patients
67%), while in the other four regions the majority of cases
re pediatric patients.13 This data corroborates the higher fre-
uency of BL in the present study, which is composed entirely
y adult patients from southern Brazil.
According to data from the Ministry of Health of Brazil,
he city of Florianopolis is third in the ranking of Brazilian
ities in terms of HIV detection and mortality rates; in fact, the
outh leads the ranking of the highest detection rates (∼2.3×
he country rate).14 The high local prevalence of HIV infection
ay have led to the high rate of BL in the present study, since
here is an increased risk of developing BL in patients with HIV
nfection.15The frequency of patients with MBCN who  were seropos-
itive for HIV was 9.7%, which is higher than the results
found by Shiels et al. These authors assessed 115,643 North
American NHL cases and observed a rate of 5.9% of HIV
infection.16 MBCN subtypes that have been associated with
this infection include DLBCL, BL, Hodgkin’s lymphoma (HL),
primary effusion lymphoma and plasmablastic lymphoma of
the oral cavity.7 Of the subjects in the current study who  were
seropositive for HIV, four had BL, two had BCL-U and two
had plasmablastic lymphoma of the oral cavity. On the other
hand, PCN are not commonly associated with HIV infection
and these neoplasms usually affect older individuals.17 How-
ever, there are reports of MM developing in younger patients
with HIV, a ﬁnding that is compatible with a case of MM in a
43-year-old HIV-positive subject in this series.
Studies have demonstrated an association between smok-
ing and the development of lymphomas, speciﬁcally FL.18,19
Of the 12 current smokers included in this study, four were
diagnosed with FL. In addition, four cases were diagnosed
with CLL/SLL; however, no association between CLL/SLL and
smoking was found in the literature.
According to the 2008 data from the Ministry of Agri-
culture, Brazil surpassed the United States in pesticide use,
and it is now the world’s largest market. This fact highlights
the importance of studies that investigate the relationship
between these potential carcinogens and the health of the
population exposed to them.20 In this study, seven patients
reported occupational exposure to pesticides. Of  these, three
were diagnosed with a subtype of PCN while three others
were diagnosed with CLL/SLL. These results are similar to
126  rev bras hematol hemoter.
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Figure 4 – Treatment response assessed as complete/partial
remission and relapsed/progressive disease.
MM:  multiple myeloma; CLL/SLL: chronic lymphocytic
leukemia/small lymphocytic lymphoma; DLBCL: diffuse
large B-cell lymphoma; FL: follicular lymphoma; BL:
Burkitt’s lymphoma.
those from a previous study, which found a positive associ-
ation between individuals exposed to speciﬁc pesticides and
the development of MM  and CLL/SLL.8
In this study, the median age at diagnosis was 58 years
similar to another Brazilian study that reported a median
age of 50 years for NHL patients.12 Conversely, a world-
wide epidemiological study showed that the median age of
patients diagnosed with lymphomas is around 70 years, with
only a few subtypes, such as FL, BL and primary mediasti-
nal lymphoma, affecting younger patients.3 Indeed, in the
present study BL patients presented a median age of 33 years
which was statistically different to that of other subtypes
of BCL.
MBCN may have a clinical course ranging from indolent to
extremely aggressive.2,21 Thus, apart from correct diagnosis,
prognostic stratiﬁcation is fundamental to deﬁne the medical
strategy, which can range from just a watch-and-wait strat-
egy to combined chemotherapy regimens.22 Considering BCL,
the most important laboratory tests to evaluate the degree of
neoplasm aggressiveness are serum LDH enzyme activity and
the percentage of Ki-67 protein evaluated using IHC. Since the
1970s, high serum LDH activity is considered an independent
poor prognostic factor.23 In the present study, a signiﬁcant 2 0 1 6;3  8(2):121–127
difference between BCL subtypes was observed in respect to
this parameter. The highest values were observed in BL with
a median of 1534 IU/L (range: 243–7239 IU/L). Moreover, serum
LDH activity was individually analyzed among BL patients and
showed that in only one case the activity of this enzyme at
diagnosis was less than 500 IU/L (243 IU/L). Interestingly, this
was also the only patient who achieved CR/PR with treatment,
and is in a good general condition.
More recently, the evaluation of Ki-67 expression has been
considered a prognostic factor for lymphomas, since it indi-
cates the cell proliferation rate.24 Thus, as found for LDH
activity, the highest values of Ki-67 expression were observed
in cases of BL, DLBCL, and BLC-U. These results are similar to
those reported by Broyde et al., who showed the expression
of Ki-67 in DLBCL, FL, CLL/SLL, atypical BL, and MCL  as 67.5%,
32.1%, 10.8%, 96.5%, and 40.2%, respectively.24
Furthermore, the most common subtypes of MCBN were
stratiﬁed according to prognostic indexes in order to establish
the stage of the tumor at diagnosis. Of the MM cases (n = 22),
54.6% (n = 12) were stratiﬁed as international staging system
(ISS) III, i.e., the highest risk category for this type of neoplasm.
Of these 12 patients, four died within, on average, 11 months of
diagnosis. A different proﬁle was found when prognostic strat-
iﬁcation of 756 patients was assessed in a previous study that
included data from 16 Brazilian Institutions with MM  cases
diagnosed between 1998 and 2004. The results showed that
20.1% of patients were stratiﬁed as ISS I, 48.7% as ISS II, and
31.2% as ISS III.25 On the other hand, a Chinese study evalu-
ated 264 cases of MM classiﬁed as 8.7% ISS I, 36.4% ISS II, and
54.9% ISS III,26 which is similar to the frequencies found in the
present study. Diagnosis of MM in advanced stages could be
related to lack of information and unspeciﬁc symptoms such
as bone lesions, which lead patients to seek other medical
specialties and often resort to self-medication.
With a different proﬁle, 64.3% (n = 9) of patients diagnosed
with CLL/SLL (n = 14) were stratiﬁed in lower risk stages includ-
ing 0 and I of the Rai system and A of the Binet system. This
data is similar to the results of a study published in 2014 that
evaluated 924 cases of CLL/SLL and found the following fre-
quencies for the Rai system: 58% were classiﬁed as stage 0,
34% as I/II and 8% as III/IV; and for the Binet system: 93%
were classiﬁed as A/B, and 7% as C. According to the litera-
ture, stages 0 and A are related to a higher overall survival
(OS), with an expected median of about ten years. Rai stages I
and II and Binet stage B have intermediate median OS of ﬁve
to seven years, while the most aggressive groups (Rai III and
IV and Binet C) have a much shorter median OS of less than
three years.27
Limitations of this study include the small patient sample
size and the short follow-up period. The lack of information on
HIV, HBV and HCV status is another potential source of bias.
Conclusion
This study demonstrates the proﬁle of patients diagnosed with
MBCN in a university hospital in southern Brazil, and com-
pared the results with national and international data. Of the
BCL, BL presented particular features regarding LDH levels,
Ki-67 expression, age at diagnosis, and HIV infection.
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